Skip to main content
SpringerLink
Log in

Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer

Breast Cancer Research and Treatment volume 127, pages 601–610 (2011)Cite this article

Abstract

Male breast cancer (MBC) is a poorly characterized disease because of its rarity. Clinical management is based on results obtained from randomized trials conducted in women notwithstanding data in the literature suggesting relevant gender-associated differences in terms of biological and clinical behavior. However, a genome-wide characterization of MBC on a transcriptional level is lacking. In this study, gene expression profiles of 37 estrogen receptor positive (ER+) MBC specimens were compared to that of 53 ER+ Female Breast Cancer (FBC) samples similar for clinical and patho-biological features. Almost 1000 genes were found differentially expressed (FDR < 1%) between female and male patients and biological interpretation highlighted a gender-associated modulation of key biological processes ranging from energy metabolism to regulation of translation and matrix remodeling as well as immune system recruitment. Moreover, an analysis of genes correlated to steroid receptors and ERBB2 suggested a prominent role for the androgen receptor in MBC with a minor relevance for progesterone receptor and ERBB2, although, similarly to FBC, a genomic amplification could be observed. Our findings support the idea that breast cancer is a quite different disease in male and female patients and the underlying gender-related biological differences are likely to have clinical implications connected with different susceptibility to treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H (2008) Male breast cancer: is the scenario changing. World J Surg Oncol 6:58

    Article  PubMed  Google Scholar 

  2. Nahleh Z, Girnius S (2006) Male breast cancer: a gender issue. Nat Clin Pract Oncol 3:428–437

    Article  PubMed  Google Scholar 

  3. Willsher PC, Leach IH, Ellis IO, Bourke JB, Blamey RW, Robertson JF (1997) A comparison outcome of male breast cancer with female breast cancer. Am J Surg 173:185–188

    Article  PubMed  CAS  Google Scholar 

  4. Goss PE, Reid C, Pintilie M, Lim R, Miller N (1999) Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer 85:629–639

    Article  PubMed  CAS  Google Scholar 

  5. Munoz de Toro MM, Maffini MV, Kass L, Luque EH (1998) Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 67:333–339

    Article  PubMed  CAS  Google Scholar 

  6. Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud E, Robertson C, Maiorano E, Veronesi P, Nole F, Mandala M, Ferretti G, Viale G, Goldhirsch A (2002) Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol 13:895–902

    Article  PubMed  CAS  Google Scholar 

  7. Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D (2001) Status of HER-2 in male and female breast carcinoma. Am J Surg 182:389–392

    Article  PubMed  CAS  Google Scholar 

  8. Weber-Chappuis K, Bieri-Burger S, Hurlimann J (1996) Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 32A:1686–1692

    Article  PubMed  CAS  Google Scholar 

  9. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800

    Article  PubMed  CAS  Google Scholar 

  10. Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM, Rosenberg A (2009) MicroRNA expression profiling of male breast cancer. Breast Cancer Res 11:R58

    Article  PubMed  Google Scholar 

  11. Ronchi E, Granata G, Brivio M, Coradini D, Miodini P, Di Fronzo G (1986) A double-labeling assay for simultaneous estimation and characterization of estrogen and progesterone receptors using radioiodinated estradiol and tritiated Org 2058. Tumori 72:251–257

    PubMed  CAS  Google Scholar 

  12. Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, Bajetta E, Celio L, Greco M, Fabbri A, Pierotti MA, Daidone MG (2008) Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr Relat Cancer 15:439–449

    Article  PubMed  CAS  Google Scholar 

  13. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116–5121

    Article  PubMed  CAS  Google Scholar 

  14. Alexa A, Rahnenfuhrer J, Lengauer T (2006) Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 22:1600–1607

    Article  PubMed  CAS  Google Scholar 

  15. Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270

    PubMed  CAS  Google Scholar 

  16. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033

    Article  PubMed  CAS  Google Scholar 

  17. Putignani L, Raffa S, Pescosolido R, Aimati L, Signore F, Torrisi MR, Grammatico P (2008) Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res Treat 110:439–452

    Article  PubMed  CAS  Google Scholar 

  18. Sennoune SR, Luo D, Martinez-Zaguilan R (2004) Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem Biophys 40:185–206

    Article  PubMed  CAS  Google Scholar 

  19. Neumann CA, Fang Q (2007) Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7:375–380

    Article  PubMed  CAS  Google Scholar 

  20. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD (2008) Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 10:1941–1988

    Article  PubMed  CAS  Google Scholar 

  21. Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68:631–634

    Article  PubMed  CAS  Google Scholar 

  22. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25:6416–6422

    Article  PubMed  CAS  Google Scholar 

  23. Caraglia M, Budillon A, Vitale G, Lupoli G, Tagliaferri P, Abbruzzese A (2000) Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur J Biochem 267:3919–3936

    Article  PubMed  CAS  Google Scholar 

  24. Perez-Martinez X, Funes S, Camacho-Villasana Y, Marjavaara S, Tavares-Carreon F, Shingu-Vazquez M (2008) Protein synthesis and assembly in mitochondrial disorders. Curr Top Med Chem 8:1335–1350

    Article  PubMed  CAS  Google Scholar 

  25. Hunt JT (2009) Discovery of ixabepilone. Mol Cancer Ther 8:275–281

    Article  PubMed  CAS  Google Scholar 

  26. Cigler T, Vahdat LT (2010) Eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 11:1587–1593

    Article  PubMed  CAS  Google Scholar 

  27. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420:629–635

    Article  PubMed  CAS  Google Scholar 

  28. Vega FM, Ridley AJ (2008) Rho GTPases in cancer cell biology. FEBS Lett 582:2093–2101

    Article  PubMed  CAS  Google Scholar 

  29. Howlin J, Rosenkvist J, Andersson T (2008) TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res 10:R36

    Article  PubMed  Google Scholar 

  30. Chia WJ, Tang BL (2009) Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta 1795:110–116

    PubMed  CAS  Google Scholar 

  31. Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, Sabe H (2004) Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci USA 101:6647–6652

    Article  PubMed  CAS  Google Scholar 

  32. Rensen WM, Mangiacasale R, Ciciarello M, Lavia P (2008) The GTPase Ran: regulation of cell life and potential roles in cell transformation. Front Biosci 13:4097–4121

    Article  PubMed  CAS  Google Scholar 

  33. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 9:188

    Article  PubMed  Google Scholar 

  34. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14:5555–5564

    Article  PubMed  CAS  Google Scholar 

  35. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518–527

    Article  PubMed  CAS  Google Scholar 

  36. Bosman FT, Stamenkovic I (2003) Functional structure and composition of the extracellular matrix. J Pathol 200:423–428

    Article  PubMed  CAS  Google Scholar 

  37. Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52:715–738

    Article  PubMed  Google Scholar 

  38. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37

    Article  PubMed  Google Scholar 

  39. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68:5405–5413

    Article  PubMed  CAS  Google Scholar 

  40. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11:R15

    Article  PubMed  Google Scholar 

  41. Materna V, Stege A, Surowiak P, Priebsch A, Lage H (2006) RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun 348:153–157

    Article  PubMed  CAS  Google Scholar 

  42. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC (2005) ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 4:18

    Article  PubMed  Google Scholar 

  43. He L, Vasiliou K, Nebert DW (2009) Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 3:195–206

    PubMed  CAS  Google Scholar 

  44. Britsch S (2007) The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 190:1–65

    Article  PubMed  Google Scholar 

  45. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N (2005) C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113:678–682

    Article  PubMed  CAS  Google Scholar 

  46. Harada N, Ohmori Y, Yamaji R, Higashimura Y, Okamoto K, Isohashi F, Nakano Y, Inui H (2008) ARA24/Ran enhances the androgen-dependent NH2- and COOH-terminal interaction of the androgen receptor. Biochem Biophys Res Commun 373:373–377

    Article  PubMed  CAS  Google Scholar 

  47. Kang HY, Yeh S, Fujimoto N, Chang C (1999) Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274:8570–8576

    Article  PubMed  CAS  Google Scholar 

  48. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP (2002) AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol 16:85–99

    Article  PubMed  CAS  Google Scholar 

  49. Schrantz N, da Silva Correia J, Fowler B, Ge Q, Sun Z, Bokoch GM (2004) Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling. J Biol Chem 279:1922–1931

    Article  PubMed  CAS  Google Scholar 

  50. Rudlowski C, Friedrichs N, Faridi A, Fuzesi L, Moll R, Bastert G, Rath W, Buttner R (2004) Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 84:215–223

    Article  PubMed  CAS  Google Scholar 

  51. Fonseca RR, Tomas AR, Andre S, Soares J (2006) Evaluation of ERBB2 gene status and chromosome 17 anomalies in male breast cancer. Am J Surg Pathol 30:1292–1298

    Article  PubMed  Google Scholar 

  52. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM (2008) A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14:1744–1752

    Article  PubMed  CAS  Google Scholar 

  53. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368

    Article  PubMed  CAS  Google Scholar 

  54. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JMS, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Supported in part by Associazione Italiana per la Ricerca sul Cancro (PIs, MA Pierotti and MG Daidone), Progetto Integrato Oncologia from the Italian Health Ministry (PI, MG Daidone), Alleanza Contro il Cancro (PI, MG Daidone).

Conflict of interest statement

The authors declared that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, via Amadeo 42, 20133, Milan, Italy

    Maurizio Callari, Vera Cappelletti, Loris De Cecco, Valeria Musella, Patrizia Miodini, Silvia Veneroni, Manuela Gariboldi & Maria Grazia Daidone

  2. Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Via Adamello 16, 20139, Milan, Italy

    Loris De Cecco & Manuela Gariboldi

  3. Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy

    Marco Alessandro Pierotti

Authors
  1. Maurizio Callari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera Cappelletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Loris De Cecco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valeria Musella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Patrizia Miodini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Silvia Veneroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manuela Gariboldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marco Alessandro Pierotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria Grazia Daidone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marco Alessandro Pierotti or Maria Grazia Daidone.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 39 kb)

Supplementary material 2 (XLS 34 kb)

Supplementary material 3 (XLS 21 kb)

Supplementary material 4 (XLS 21 kb)

Supplementary material 5 (DOC 394 kb)

10549_2010_1015_MOESM6_ESM.jpg

Clustering analysis with PgR associated genes. Using a set of clones differentially expressed between PgR+ and PgR− MBC samples, a hierarchical clustering analysis was performed on the MBC dataset itself (A) as well as on our FBC dataset (B) and on the Chanrion FBC dataset (C) samples. A sub-cluster containing 7/8 PgR− tumors was noticed in the clustering of MBC samples, while a quite random distribution of PgR− tumors was observed in FBC datasets (JPG 111 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Callari, M., Cappelletti, V., De Cecco, L. et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 127, 601–610 (2011). https://doi.org/10.1007/s10549-010-1015-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1015-8

Keywords

search

Navigation